Immunologic characterization of herpes simplex virus type 2 antigens ICP10 and ICSP11/12
- PMID: 2988230
- DOI: 10.1016/0168-1702(85)90012-7
Immunologic characterization of herpes simplex virus type 2 antigens ICP10 and ICSP11/12
Abstract
Infected cell protein 10 (ICP10) or antigen 4 (Ag4) and infected cell-specific protein 11/12 (ICSP11/12) have been suggested as specific antigenic markers for cervical carcinoma. Experiments were designed to determine whether ICP10 and ICSP11/12 are distinct antigens and to determine the cellular localization of ICP10. Results indicate that an apparent 160 kdalton (kDa) protein analyzed by 8.5% polyacrylamide gels (= 144 kDa protein analyzed by 7.0% polyacrylamide gels) was detected in HSV-2-infected but not mock-infected extracts. This protein is an early virus-induced protein appearing 2-4 h after HSV-2 infection, and it was synthesized in the presence of successive blocks with cycloheximide and actinomycin D. These properties are characteristic for ICP10 (Ag4), thus establishing the identity of the 160 kDa/144 kDa protein as ICP10. Furthermore, Western blot analyses indicated that ICP10 and ICSP11/12 are distinct antigens recognized by antibodies in sera from immune rabbit or human cervical carcinoma patients. In addition, monoclonal antibodies to the HSV-2-induced ribonucleotide reductase were reactive with ICP10. Antibodies in sera from rabbits immunized against ICP10 and monoclonal antibodies to the HSV-2-induced ribonucleotide reductase were reactive with antigens on the plasma membrane surface of HSV-2-infected cells. Also, the reactivity of monoclonal antibodies with these antigens was blocked by the rabbit antibodies based on immunofluorescence analyses. These data provide evidence that ICP10 is antigenically distinct from ICSP11/12, and that ICP10 is present on the plasma membrane of HSV-2-infected cells. Also, our data confirm and extend the tentative identification of ICP10 with the HSV-2-induced ribonucleotide reductase recently suggested by Bacchetti et al. (J. Virol. 49, 591-593, 1984).
Similar articles
-
Immunological characterization of herpes simplex virus type 1 and 2 polypeptide(s) involved in viral ribonucleotide reductase activity.J Virol. 1984 Feb;49(2):591-3. doi: 10.1128/JVI.49.2.591-593.1984. J Virol. 1984. PMID: 6319760 Free PMC article.
-
The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway.J Virol. 2002 Feb;76(3):1435-49. doi: 10.1128/jvi.76.3.1435-1449.2002. J Virol. 2002. PMID: 11773417 Free PMC article.
-
Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10).Vaccine. 1999 Apr 9;17(15-16):1951-63. doi: 10.1016/s0264-410x(98)00470-8. Vaccine. 1999. PMID: 10217594
-
The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2.Virology. 1996 Feb 1;216(1):184-96. doi: 10.1006/viro.1996.0045. Virology. 1996. PMID: 8614985
-
Herpes simplex virus antigens and antibodies: a survey of studies based on quantitative immunoelectrophoresis.Rev Infect Dis. 1980 Nov-Dec;2(6):899-913. doi: 10.1093/clinids/2.6.899. Rev Infect Dis. 1980. PMID: 6164087 Review.
Cited by
-
Protein kinase activity associated with the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).J Virol. 1989 Aug;63(8):3389-98. doi: 10.1128/JVI.63.8.3389-3398.1989. J Virol. 1989. PMID: 2545912 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources